Aurinia Pharmaceuticals Inc.

NasdaqGM:AUPH 주식 보고서

시가총액: US$1.0b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Aurinia Pharmaceuticals 관리

관리 기준 확인 1/4

Aurinia Pharmaceuticals' CEO는 Peter Greenleaf, Apr2019 에 임명되었습니다 의 임기는 5.17 년입니다. 총 연간 보상은 $ 10.57M, 7.8% 로 구성됩니다. 7.8% 급여 및 92.2% 보너스(회사 주식 및 옵션 포함). 는 $ 1.69M 가치에 해당하는 회사 주식의 0.22% 직접 소유합니다. 1.69M. 경영진과 이사회의 평균 재임 기간은 각각 4 년과 4.6 년입니다.

주요 정보

Peter Greenleaf

최고 경영자

US$10.6m

총 보상

CEO 급여 비율7.8%
CEO 임기5.4yrs
CEO 소유권0.2%
경영진 평균 재임 기간4.3yrs
이사회 평균 재임 기간1.1yrs

최근 관리 업데이트

Recent updates

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Sep 06
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Surges 30% Yet Its Low P/S Is No Reason For Excitement

Aurinia Pharmaceuticals Appears Undervalued

Jul 05

We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

May 24
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report

May 05
Analysts Have Made A Financial Statement On Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) First-Quarter Report

Aurinia Pharma: A Welcome Change To The Thesis (Rating Upgrade)

May 02

Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024

Apr 18

Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed

Mar 05

Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report

Feb 19
Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report

Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues

Feb 17
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues

Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon

Feb 15

Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential

Jan 28

We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Jan 05
We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow

Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price

Dec 18
Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price

Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business

Sep 14
Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business

Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement

Jun 11
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement

Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher

May 09
Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher

We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn

May 01
We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%

Nov 04
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%

Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus

Sep 19

Aurinia Pharmaceuticals: The Right Play Now

Aug 24

Aurinia Pharmaceuticals: Updating My Revenue And Valuation Model

Aug 15

CEO 보상 분석

Peter Greenleaf 의 보수는 Aurinia Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$50m

Mar 31 2024n/an/a

-US$63m

Dec 31 2023US$11mUS$823k

-US$78m

Sep 30 2023n/an/a

-US$77m

Jun 30 2023n/an/a

-US$73m

Mar 31 2023n/an/a

-US$97m

Dec 31 2022US$9mUS$791k

-US$108m

Sep 30 2022n/an/a

-US$115m

Jun 30 2022n/an/a

-US$157m

Mar 31 2022n/an/a

-US$168m

Dec 31 2021US$1mUS$724k

-US$181m

Sep 30 2021n/an/a

-US$156m

Jun 30 2021n/an/a

-US$148m

Mar 31 2021n/an/a

-US$127m

Dec 31 2020US$11mUS$673k

-US$103m

Sep 30 2020n/an/a

-US$129m

Jun 30 2020n/an/a

-US$110m

Mar 31 2020n/an/a

-US$102m

Dec 31 2019US$5mUS$438k

-US$88m

보상 대 시장: Peter 의 총 보상 ($USD 10.57M )은 US 시장( $USD 3.31M ).

보상과 수익: 회사가 수익성이 없는 동안 Peter 의 보상이 증가했습니다.

CEO

Peter Greenleaf (54 yo)

5.4yrs

테뉴어

US$10,573,359

보상

Mr. Peter S. Greenleaf, M.B.A., is Director at NVN Liquidation Inc. He serves as Director at ValenzaBio, Inc. since August 2022. He has been President, Chief Executive Officer and Director of Aurinia Pharm...

리더십 팀

이름위치테뉴어보상소유권
Peter Greenleaf
President5.4yrsUS$10.57m0.22%
$ 2.3m
Joseph Miller
Chief Financial Officer4.4yrsUS$3.98m0.078%
$ 816.3k
Matthew Donley
Executive Vice President of Operations & Strategyno dataUS$4.56m0.11%
$ 1.1m
Stephen Robertson
Executive VP3.8yrsUS$3.60m0.055%
$ 570.5k
Andrea Christopher
Head of the Corporate Communications & Investor Relationsno data데이터 없음데이터 없음
Michael Martin
Chief Business Officer4.3yrsUS$702.00k데이터 없음
Sue Evans
Senior Vice President of Global Regulatory Affairsno data데이터 없음데이터 없음
Scott Habig
Chief Commercial Officer2.2yrs데이터 없음0.071%
$ 739.1k
Gregory Keenan
Chief Medical Officerno data데이터 없음데이터 없음
Ann Daus
Senior Vice President of Qualityno data데이터 없음데이터 없음
Premchandran Ramiya
Senior Vice President of Manufacturing & Supply Chainno data데이터 없음데이터 없음
DeDe Sheel
Vice President of Investor Relationno data데이터 없음데이터 없음

4.3yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: AUPH 의 관리팀은 경험 ( 4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Peter Greenleaf
President5.4yrsUS$10.57m0.22%
$ 2.3m
Kevin Tang
Directorno data데이터 없음데이터 없음
Robert Foster
Directorless than a yearUS$474.21k0%
$ 0
Jill Leversage
Independent Director4.8yrsUS$267.28k0.010%
$ 107.1k
Jeffrey Bailey
Independent Director1.1yrsUS$361.51k0%
$ 0
Karen Smith
Independent Director1.1yrsUS$359.41k0%
$ 0
David R. Jayne
Independent Non-Executive Director9.3yrsUS$249.92k0.031%
$ 323.0k

1.1yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: AUPH 의 이사회는 경험(평균 재직 기간 1.1 년)으로 간주되지 않으므로 새 이사회가 필요합니다.